Studies reported that overexpression of Oct4 and Sox2 were associated with drug-resistance, including chemotherapy, radiation therapy and target therapy in lung cancer and bladder cancer, malignant mesothelioma cells and osteosarcoma [39–42]. Here, SOX2 is linked to lung carcinoma.